Summary
This 10-K filing for Johnson & Johnson for the fiscal year ended January 2, 2011, provides a comprehensive overview of the company's operations, financial condition, and risk factors. As a large accelerated filer, J&J operates across diverse segments including Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Care. The report indicates a robust market presence and ongoing commitment to research and development, crucial for sustaining its competitive edge in the healthcare industry. Investors should note the company's extensive patent portfolio and the highly regulated nature of its business, which are key considerations for understanding its long-term prospects and potential challenges. While specific financial figures for revenue, net income, and cash flow are not detailed in the provided excerpt, the filing references the incorporation of the Annual Report to Shareholders and Proxy Statement for more granular financial data. The company's substantial market capitalization, exceeding $163 billion, underscores its significant position in the market. Investors should pay close attention to the 'Risk Factors' section (Item 1A) for a detailed understanding of potential headwinds, and the 'Management's Discussion and Analysis of Financial Condition and Results of Operation' (Item 7) for management's perspective on performance and outlook. The extensive list of exhibits, particularly those related to executive compensation and corporate governance, also offers insights into the company's structure and shareholder-related policies.
Financial Highlights
55 data points| Revenue | $61.59B |
| Cost of Revenue | $18.79B |
| Gross Profit | $42.80B |
| SG&A Expenses | $19.42B |
| Operating Income | $17.70B |
| Interest Expense | $455.00M |
| Net Income | $13.33B |
| EPS (Basic) | $4.85 |
| EPS (Diluted) | $4.78 |
| Shares Outstanding (Basic) | 2.75B |
| Shares Outstanding (Diluted) | 2.79B |
Key Highlights
- 1Johnson & Johnson is a large accelerated filer, indicating its significant size and established reporting history.
- 2The company operates across multiple segments: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Care.
- 3J&J has a substantial market capitalization, estimated at approximately $163 billion based on common stock held by non-affiliates as of the last business day of the second fiscal quarter.
- 4The filing incorporates by reference the Annual Report to Shareholders and Proxy Statement for detailed financial data and operational discussions.
- 5Key areas for investor review include 'Risk Factors' (Item 1A) and 'Management's Discussion and Analysis' (Item 7).
- 6The company holds numerous patents and trademarks, which are critical assets in the competitive healthcare landscape.
- 7J&J operates in a highly regulated industry, with significant implications for its business operations and product development.